Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center

February 11, 2009

BOCA RATON, Fla., Feb. 11 /PRNewswire/ — Biotest Pharmaceuticals
Corporation (BPC), a wholly owned subsidiary of Biotest AG, Dreieich, Germany,
announced that it has acquired a plasma collection facility located at 2860
Cerrillos Road, Santa Fe, New Mexico from Talecris Plasma Resources, Inc.
With this acquisition, BPC now operates 11 plasma centers in various locations
throughout the United States. Last year, the company announced it had
aggressive plans for further expansion during the next two years. BPC will
continue to explore opportunities to expand its plasma collection operations
to address the global demand for this very important source material.
Financial terms of the purchase were not disclosed.

“We are extremely pleased to add the Santa Fe facility to our network of
plasma centers in the U.S.,” remarked Dr. Rainer Pabst, Chief Executive
Officer of BPC. “We are looking forward to continuing to build upon our
existing foundation to reach our goals of continued growth and expanded range
of top-quality plasma products.”

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation develops and manufactures
pharmaceutical and biotherapeutic products with a specialization in
immunology. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest
AG acquisition of Nabi Pharmaceuticals’ Biologics business unit, including its
plasmapheresis centers across the United States. The company employs
approximately 560 people in the U.S. Biotest Pharmaceuticals is a subsidiary
of Biotest AG, a German-based global provider of plasma proteins that employs
approximately 1,850 people worldwide.

To learn more about Biotest Pharmaceuticals and how we help make a
difference in the lives of patients and the healthcare community, please visit
us at www.biotestpharma.com

About Biotest AG

Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialized in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on human
blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches into
the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic segment
spans reagents and immunological diagnostics which are used, for example, in
blood transfusions and transplants. Biotest has around 1,950 employees
worldwide and its shares are listed in the Stock Exchange’s SDAX on the
Frankfurt Stock Exchange.

SOURCE Biotest Pharmaceuticals Corporation

Source: newswire

comments powered by Disqus